Fraxinus Excelsior Pollen

Dosage for Fraxinus Excelsior Pollen is highly individualized and is never 'one size fits all.' The dosage is measured in Weight/Volume (w/v) or Protein Nitrogen Units (PNU), as it is a non-standardized extract.

Diagnostic Dosing

• Skin Prick Test (SPT): Usually, a single drop of the 1:10 or 1:20 w/v glycerinated extract is applied to the skin, which is then pricked with a sterile lancet.
• Intradermal Test: If the SPT is negative but clinical suspicion remains high, a 1:1000 or 1:500 w/v aqueous solution (0.02 mL) may be injected into the dermis.

Immunotherapy Dosing (SCIT)

Immunotherapy follows a two-phase schedule:

1. 1Build-up (Escalation) Phase: Injections are typically given 1–2 times per week. The starting dose is very low (e.g., 0.05 mL of a 1:10,000 w/v dilution) and is gradually increased over 3–6 months until the maintenance dose is reached.
2. 2Maintenance Phase: Once the maximum tolerated dose is reached (e.g., 0.5 mL of a 1:10 or 1:20 w/v solution), the frequency of injections is reduced to once every 2–4 weeks. This phase usually lasts for 3–5 years to ensure long-term desensitization.

Fraxinus Excelsior Pollen is generally considered safe for use in children, typically those aged 5 years and older. Use in children under 5 is rare and requires careful consideration of the child's ability to cooperate with the procedure and communicate symptoms of a systemic reaction.

• Dosing: The dosing schedule for children is often identical to that of adults, though the physician may choose a more conservative build-up phase depending on the child's sensitivity and the presence of concomitant asthma.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the proteins are not cleared by the kidneys in a manner that affects toxicity. However, the patient's overall health should be stable.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. The metabolism of allergenic extracts does not rely on the cytochrome P450 system.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (the primary treatment for a severe reaction) may be riskier in this population. Healthcare providers may choose a slower build-up phase.

Fraxinus Excelsior Pollen extracts MUST be administered in a clinical setting under the direct supervision of a healthcare professional trained in the management of anaphylaxis.

• Administration: Subcutaneous injection is given in the posterior aspect of the upper arm. The site should be rotated between the left and right arms for each visit.
• Observation: Patients MUST remain in the doctor's office for at least 30 minutes after every injection. Most fatal or near-fatal systemic reactions occur within this window.
• Storage: Vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the extract away from light to prevent protein degradation.
• Pre-medication: Some doctors may recommend taking an oral antihistamine before the injection to reduce the risk of large local reactions, though this does not prevent anaphylaxis.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay. If a dose is missed during the maintenance phase:

• 1-2 weeks late: Usually, the same dose can be given.
• 3-4 weeks late: The dose may be reduced by 25-50%.
• Over 4 weeks late: The build-up may need to be partially restarted.

An overdose of allergenic extract usually occurs due to a dosing error or a sudden increase in the patient's sensitivity (e.g., during peak allergy season).

• Signs: Rapid onset of hives, swelling of the throat, wheezing, shortness of breath, or a drop in blood pressure.
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3 mg for adults) is the first-line treatment. Oxygen, IV fluids, and corticosteroids may also be required.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or skip visits without medical guidance, as this increases the risk of a reaction.

Most patients receiving Fraxinus Excelsior Pollen immunotherapy will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness and Swelling: A 'wheal' or hard bump at the injection site is very common. This may feel itchy or warm to the touch. It typically appears within minutes and resolves within 24 hours.
• Pruritus (Itching): Intense itching at the site of the injection or skin test is a standard response to the histamine release triggered by the extract.
• Fatigue: Some patients report feeling unusually tired for a few hours after receiving an immunotherapy injection.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. This may involve the entire upper arm and can be painful. While not a systemic risk, an LLR often prompts a dose adjustment for the next visit.
• Nasal Congestion and Sneezing: A mild 'flare' of hay fever symptoms shortly after the injection.
• Headache: Some patients experience mild tension-type headaches following treatment.

• Generalized Urticaria (Hives): Itching and hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Persistent Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).

> Warning: Stop taking Fraxinus Excelsior Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or a persistent cough. This indicates that the allergen is affecting the lower airways.
• Laryngeal Edema: A feeling of a 'lump in the throat,' difficulty swallowing, or a hoarse voice, indicating airway swelling.
• Hypotension (Low Blood Pressure): Feeling faint, dizzy, or suddenly weak. This can lead to loss of consciousness (anaphylactic shock).
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after an injection.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Fraxinus Excelsior Pollen. Because it is a natural protein extract, it does not accumulate in organs or cause cancer. The primary long-term 'effect' is the desired modification of the immune system. However, patients with pre-existing autoimmune diseases should be monitored closely, as there is a theoretical (though largely unproven) risk that chronic immune stimulation could affect their condition.

While Fraxinus Excelsior Pollen may not have a specific 'Black Box' in all jurisdictions, the FDA requires a General Warning for all allergenic extracts regarding the risk of severe systemic reactions.

Summary of Warning:

• This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• It must only be administered by healthcare providers equipped with the tools and training to treat anaphylaxis.
• Patients with unstable or severe asthma are at a significantly higher risk of fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.

Report any unusual symptoms, even if they seem minor, to your healthcare provider before your next scheduled dose.

Fraxinus Excelsior Pollen is a potent biological agent. Its use is restricted to patients with a clear clinical history of allergy and a confirmed positive skin test or blood test. It is not a 'cure' in the traditional sense but a long-term desensitization process that requires strict adherence to safety protocols.

No specific FDA black box warning exists for Fraxinus Excelsior specifically, but the entire class of Allergenic Extracts carries a class-wide warning regarding the risk of anaphylaxis. The warning emphasizes that injections must be given in a medical setting, and patients must be observed for at least 30 minutes. It also notes that the risk of a fatal reaction is higher in patients with symptomatic or poorly controlled asthma.

Allergic Reactions / Anaphylaxis Risk

The most significant risk is a systemic allergic reaction. This risk is higher during the build-up phase, during peak ash pollen season, or if the patient is ill (e.g., has a viral infection). Patients should be instructed to avoid vigorous exercise for several hours after an injection, as increased blood flow can accelerate the absorption of the allergen.

Asthma Status

Patients with asthma must be stable before receiving an injection. If a patient is experiencing increased wheezing or has a low peak flow reading on the day of the injection, the dose should be postponed. Uncontrolled asthma is the single greatest risk factor for a fatal reaction to immunotherapy.

Cardiovascular Health

Patients with significant heart disease may be at higher risk if a systemic reaction occurs, as the physiological stress of anaphylaxis and the subsequent administration of epinephrine can strain the heart.

• Observation Window: Every patient must be monitored for 30 minutes post-injection.
• Peak Flow Meter: For asthmatic patients, a peak flow reading may be taken before the injection to ensure lung function is at its baseline.
• Symptom Tracking: Patients should keep a log of any local reactions (size and duration) to help the doctor adjust the dosage.
• Vitals: In some cases, blood pressure and heart rate may be checked if the patient feels unwell.

Generally, Fraxinus Excelsior Pollen does not cause drowsiness. However, if a patient experiences a mild systemic reaction or feels faint after an injection, they should not drive until they are fully recovered. The use of antihistamines to treat local reactions may cause drowsiness.

There is no direct interaction between alcohol and Fraxinus Excelsior Pollen. However, alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically increase the speed of allergen absorption or worsen the symptoms of a systemic reaction. It is best to avoid alcohol for several hours after an injection.

Immunotherapy can be stopped at any time, but stopping prematurely (before 3 years) usually results in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, as they are not physically addictive and do not affect the central nervous system.

> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Fraxinus Excelsior Pollen.

There are few absolute contraindications for drug combinations, but the following are critical:

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are used for high blood pressure and heart conditions. They can block the effects of epinephrine (adrenaline). If a patient on a beta-blocker has an anaphylactic reaction to Fraxinus excelsior, the standard treatment (epinephrine) may not work, leading to a potentially fatal outcome. Many allergists consider this an absolute contraindication for immunotherapy.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some evidence suggests that ACE inhibitors may increase the risk of more severe systemic reactions or interfere with the body's natural compensatory mechanisms during anaphylaxis.
• Other Immunotherapies: If a patient is receiving 'allergy shots' for multiple allergens (e.g., grasses, dust mites, and ash pollen), the cumulative 'allergic load' is higher, increasing the risk of a systemic reaction. Doses are often staggered.

• Antihistamines (e.g., Loratadine, Cetirizine): While often used to manage side effects, antihistamines can mask the early warning signs of a systemic reaction (like itching or hives), potentially delaying the diagnosis of anaphylaxis. They also MUST be stopped several days before diagnostic skin testing, as they will cause a false-negative result.
• Tricyclic Antidepressants (TCAs): These may potentiate the effect of epinephrine if it needs to be administered, leading to dangerous spikes in blood pressure.

• Cross-Reactive Foods: Patients allergic to Fraxinus excelsior may experience 'Oral Allergy Syndrome' (OAS) with certain foods. While not a direct drug interaction, consuming these foods (like olives or certain fruits) around the time of an injection might increase the overall level of immune activation.

There are no well-documented interactions with herbal supplements. However, supplements that have immune-stimulating properties (like Echinacea) should be discussed with an allergist, as the goal of immunotherapy is to modulate the immune system in a specific way.

• Skin Tests: As mentioned, antihistamines and certain sleep aids will interfere with the results of skin testing.
• Serum IgE Tests: Fraxinus Excelsior Pollen treatment will eventually lead to changes in lab results, such as a decrease in specific IgE and an increase in specific IgG4. This is an expected therapeutic effect, not an 'interaction.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart rhythm.

Fraxinus Excelsior Pollen must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients whose asthma is not well-managed have a high risk of fatal bronchospasm if a systemic reaction occurs. The airway is already inflamed and hyper-reactive.
2. 2Recent Myocardial Infarction (Heart Attack): The stress of a potential reaction and the need for epinephrine make immunotherapy too risky in the months following a major cardiac event.
3. 3History of Severe Anaphylaxis to this Specific Extract: If a patient has previously had a life-threatening reaction to ash pollen extract despite dose adjustments, the risks outweigh the benefits.
4. 4Beta-Blocker Therapy: As noted, this prevents the effective treatment of anaphylaxis.

These conditions require a careful risk-benefit analysis by the allergist:

• Autoimmune Diseases: Conditions like Lupus or Rheumatoid Arthritis may theoretically be flared by immune stimulation, though data is limited.
• Malignancy: Patients undergoing active cancer treatment generally should not start immunotherapy.
• Severe Psychological Disorders: The patient must be able to communicate symptoms clearly and adhere to a strict, long-term schedule.
• Pregnancy (Starting Treatment): It is generally recommended not to start immunotherapy during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia.

Patients should be aware of cross-sensitivity with other members of the Oleaceae family. If you are severely allergic to Olive tree pollen, you are highly likely to react to Fraxinus Excelsior Pollen. This must be accounted for when determining the starting dose to avoid an accidental overdose.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Fraxinus Excelsior Pollen.

Fraxinus Excelsior Pollen is classified as Pregnancy Category C.

• Risk Summary: There are no adequate and well-controlled studies in pregnant women. The primary concern is not the extract itself (which is a natural protein), but the risk of a systemic reaction (anaphylaxis) in the mother. Anaphylaxis can cause a sudden drop in blood pressure, leading to decreased oxygen flow to the fetus (fetal hypoxia), which can cause permanent damage or miscarriage.
• Clinical Recommendation: Most allergists will not start a new course of immunotherapy during pregnancy. However, if a woman is already on a maintenance dose and is tolerating it well, the treatment is often continued, as the risk of a reaction is much lower during the maintenance phase than during the build-up phase.

It is generally considered safe to continue Fraxinus Excelsior Pollen immunotherapy while breastfeeding. The large protein molecules in the extract are not expected to pass into breast milk in any significant quantity, and if they did, they would be digested by the infant's gastrointestinal tract. There is no evidence of harm to nursing infants.

• Approved Age: Immunotherapy is typically indicated for children 5 years of age and older.
• Considerations: Children often have higher rates of asthma than adults, requiring stricter monitoring of lung function. The long-term benefit for children is significant, as studies suggest that treating allergic rhinitis with AIT can prevent the future development of asthma and new sensitizations to other allergens.

• Risk Profile: Patients over age 65 are at a higher risk for co-morbidities like hypertension and coronary artery disease.
• Epinephrine Safety: The use of epinephrine in an elderly patient with heart disease can trigger arrhythmias or a heart attack. Therefore, the decision to use Fraxinus Excelsior Pollen in the elderly must be highly individualized, focusing on those with severe symptoms that significantly impact their quality of life.

No dosage adjustments are needed. The proteins in the extract are broken down into amino acids by ubiquitous proteases and do not rely on renal filtration for clearance or efficacy.

No dosage adjustments are needed. Liver function does not affect the immunological processing of allergenic extracts.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you become pregnant or are planning to breastfeed while receiving treatment.

Fraxinus Excelsior Pollen acts as an immunomodulator. In the diagnostic phase, it acts as an antigen that cross-links IgE antibodies on the surface of mast cells, causing the release of histamine. In the therapeutic phase (immunotherapy), it induces a state of desensitization. This is achieved by shifting the T-cell response from Th2 (pro-allergic) to Th1 (pro-inflammatory/protective) and inducing T-regulatory cells. These cells produce IL-10, which suppresses IgE production and increases the production of IgG4 blocking antibodies. These IgG4 antibodies bind to the ash pollen allergens before they can reach the IgE on mast cells, effectively neutralizing the allergic response.

• Dose-Response: There is a clear dose-response relationship in immunotherapy. Higher doses (within the maximum tolerated range) are more effective at inducing long-term tolerance than low doses.
• Onset of Effect: Diagnostic reactions occur within 15-20 minutes. Therapeutic effects (reduction in allergy symptoms) usually take 6-12 months of consistent treatment to become noticeable.
• Duration of Effect: If a full 3-5 year course is completed, the desensitization effect can last for many years, or even decades, after the treatment is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | N/A (Immunological interaction) |

| Half-life | Minutes to hours (Proteolysis) |

| Tmax | 15-30 minutes (Local absorption) |

| Metabolism | Proteolytic degradation |

| Excretion | Not clinically relevant |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides. The primary allergenic component is Fra e 1 (an 18-20 kDa protein).
• Solubility: Soluble in aqueous buffers and saline.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various protein fractions.

Fraxinus Excelsior Pollen is a Non-Standardized Pollen Allergenic Extract. It belongs to the broader therapeutic class of Allergen Immunotherapy Agents. Related medications include extracts for Grass Pollen (e.g., Timothy grass), Weed Pollen (e.g., Ragweed), and other Tree Pollens (e.g., Birch, Oak).